19/10/2022 - Press release
A multicentre study involving hospitals in Spain and Portugal, led by Hospital del Mar, shows that these patients already receive enough radiation to treat the disease when the breast affected by the tumour is irradiated directly. The study monitored more than 400 women. The results indicate that the five-year survival rate and relapses are practically identical between those who underwent specific treatment targeting the nodes located in the armpits and those who only received breast radiation. The findings of the OPTIMAL study have been published in the journal Radiation Oncology and can now be applied to clinical practice. Thanks to this fact, patients will need less radiotherapy and will suffer fewer treatment-related side effects.
05/10/2022 - Press release
A study led by researchers at the Hospital del Mar Medical Research Institute (IMIM-Hospital del Mar) has determined the role that fibroblasts, the cells that contribute to tissue formation, play in a tumour's ability to generate resistance to the most common biological treatment for HER2. The paper, published in the journal Nature Communications, demonstrates the ability of a new therapy, currently undergoing clinical trials, to promote a potent immune response by binding to the fibroblasts, enabling it to overcome resistance to anti-HER2 therapy in tumours with this cancer cell protection mechanism. To demonstrate this, the researchers created a 3D tumour model in which they were able to check the relationships between all the factors involved.
12/09/2022 - Press release
Patients admitted due to SARS-CoV-2 infection with imbalanced levels of two immune system cells, CD4 and CD8 T lymphocytes, have a worse prognosis and a higher risk of death. Having more than twice the number of CD4 lymphocytes than CD8 lymphocytes increases the probability of dying from the infection by 4.6 times and the chances of experiencing respiratory distress by two times, according to a study by physicians and researchers from Hospital del Mar, the Hospital del Mar Medical Research Institute, Universitat Pompeu Fabra, and CIBERINFEC, published in the journal Frontiers in Medicine. This finding leads the study's authors to recommend a more aggressive therapeutic approach for these patients from the moment of admission. Additionally, they believe that this situation may be repeated in other viral infections.
11/08/2022 - Press release
The research, led by the Barcelonaβeta Brain Research Center (BBRC), research center of the Pasqual Maragall Foundation, the Hospital del Mar Medical Research Institute (IMIM-Hospital del Mar) and the University of Gothenburg, has been published in the prestigious journal Nature Medicine. The study, which used data from almost 400 participants of the ALFA+ Study, which has the impetus of the "la Caixa" Foundation, determines that the biomarkers p-tau231 and p-tau217 measured in the blood are suitable for indicating brain changes related to the amyloid protein in people without cognitive symptoms. The results of this research make p-tau231 a very promising blood biomarker to detect early those middle-aged people who show the first brain changes associated with Alzheimer's and to conduct clinical trials aimed at this early stage of Alzheimer's.
28/07/2023 - Press release
A study by cardiologists at Hospital del Mar and researchers at the Hospital del Mar Medical Research Institute reveals that more than half of the people treated for the arrhythmia known as atrial flutter will suffer an episode of atrial fibrillation in less than a year. The risk of atrial fibrillation reaches 86% in those patients who score higher on a risk scale designed by the team, prompting the need for more accurate monitoring of these patients because of the likelihood that they could suffer other cardiovascular problems, such as a stroke. The study, published in the Journal of Cardiology, was funded by the 2014 La Marató de TV3, dedicated to heart disease.
Més informació "Patients with arrhythmia are at greater risk of suffering atrial fibrillation"
30/05/2022 - Press release
A group of genes has been identified in cancerous cells that survive chemotherapy treatment. The activity of these genes leads to treatment resistance and increased capacity for metastasis. This breakthrough opens the door to studying targeted treatments using drug inhibitors of these genes combined with chemotherapy, potentially providing alternatives for patients with a worse prognosis in this type of tumor, accounting for 30% of cases. The research, led by scientists from the Hospital del Mar Medical Research Institute, highlights that this type of tumor cell reverts to an embryonic state. Identifying the factor that triggers this change could aid in designing new treatments for high-risk patients.
04/05/2022 - Press release
The Biomedical Informatics Research Programme of IMIM-Hospital del Mar has received one of the European Research Council (ERC) grants for the NovoGenePop project, the ERC Advanced Grant. Among the 253 researchers selected, only thirteen are from Spain. The project at the IMIM-Hospital del Mar, the only Spanish biomedical research centre to be selected, will develop bioinformatics tools to identify specific genes in certain individuals or populations. This may pave the way for accelerated research in fields such as cancer and hereditary diseases. In total, the ERC Advanced Grants have distributed 624 million between 253 European researchers. This is the fourth grant of this type that the IMIM-Hospital del Mar has received in the last years.
28/04/2022 - Press release
The study was carried out jointly by Germans Trias Hospital and the Hospital del Mar Medical Research Institute (IMIM-Hospital del Mar). The research team compared blood samples from 58 cases of patients hospitalised for heart attack complicated by primary ventricular fibrillation with those of 116 people who did not suffer this complication. A team of researchers from Germans Trias Hospital, the Hospital del Mar Medical Research Institute (IMIM-Hospital del Mar) and the CIBER on cardiovascular diseases has demonstrated that regular consumption of foods rich in linoleic acid can help to reduce the risk of cardiac arrest due to ventricular fibrillation during the acute phase of a heart attack. The results of the study have been published in the journal Scientific Reports.
12/04/2022 - Press release
COVID-19 has accelerated the need to raise awareness of the psychological well-being of the human teams that form part of SME organisations, in the face of the economic uncertainty aggravated by the war in Ukraine.
17/03/2022 - Press release
Researchers at the Hospital del Mar Medical Research Institute and Hospital del Mar have transformed immunotherapy-resistant tumours into tumours that respond to this treatment, achieving cures in animal models through an innovative therapeutic strategy in triple-negative breast cancer, the most aggressive subtype. Researchers have discovered the essential role of a new factor, LCOR, in enabling cancer cells to present tumour antigens on their surfaces. These antigens allow the immune system to recognise the tumour, an essential step if immunotherapy treatment is to succeed. On the other hand, they have shown that cancer stem cells have very low levels of LCOR, making them invisible to the immune system and therefore resistant to treatment. The work that has just been published used an innovative experimental messenger RNA system, similar to the technology used for COVID-19 vaccines, to produce LCOR in tumour cells. In this way, the resistant tumour cells of triple-negative cancer become visible and sensitive to the immune system. This approach is also being investigated in other breast cancer subtypes
Més informació "Radical increase in the effectiveness of breast cancer immunotherapy"
Servei de Comunicació:
Marta Calsina Freixas(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
